Logo

Genmab A/S

GMAB

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amiva… read more

Healthcare

Biotechnology

16 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$27.54

Price

+0.59%

$0.16

Market Cap

$17.378b

Large

Price/Earnings

14.3x

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

+48.4%

EBITDA Margin

+36.3%

Net Profit Margin

+5.6%

Free Cash Flow Margin
Revenue

$17.839b

-17.1%

1y CAGR

+8.8%

3y CAGR

+24.6%

5y CAGR
Earnings

$5.642b

-28.1%

1y CAGR

+10.7%

3y CAGR

+29.1%

5y CAGR
EPS

$8.79

-27.6%

1y CAGR

+12.1%

3y CAGR

+30.2%

5y CAGR
Book Value

$5.302b

$6.464b

Assets

$1.162b

Liabilities

$148m

Debt
Debt to Assets

2.3%

-

Debt to EBITDA
Free Cash Flow

$4.912b

-35.2%

1y CAGR

+22.6%

3y CAGR

+37.5%

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases